Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
[aromatase deficiency]
Cases
of
men
with
estrogen
resistance
and
aromatase
deficiency
have
highlighted
the
effects
of
estrogens
on
bone
metabolism
,
the
cardiovascular
system
and
biochemical
variables
of
the
metabolic
syndrome
.
In
eugonadal
men
,
administration
of
an
aromatase
inhibitor
induces
a
substantial
elevation
of
LH
and
testosterone
due
to
the
decreased
negative-feedback
signal
of
estrogen
and
may
thwart
the
interpretation
of
results
.
As
there
is
no
gonad
for
LH
to
act
on
,
no
increase
of
serum
testosterone
concentration
will
be
seen
in
female
-
to
-male
transssexuals
.
The
aim
of
this
study
was
to
investigate
the
effects
of
estrogen
deprivation
on
bone
metabolism
and
vascular
parameters
without
the
interference
of
counter-regulatory
effects
as
seen
in
eugonadal
men
.
Thirty
ovariectomized
female
-
to
-male
transsexuals
participated
in
this
double
-blind
,
randomized
trial
.
During
3
months
,
subjects
received
the
aromatase
inhibitor
anastrozole
1
mg
/
day
(
n
=
16
)
or
a
placebo
(
n
=
14
)
in
addition
to
parenteral
testosterone
esters
(
Sustanon
250
every
2
weeks
)
.
Serum
17
beta
-estradiol
(
E
(
2
)
)
concentration
fell
significantly
from
134
.
0
+
/
-
78
.
8
to
77
.
7
+
/
-
130
.
6
pmol
/
l
compared
with
placebo
(
P
<
0
.
01
)
.
LH
and
FSH
levels
rose
without
the
rise
of
testosterone
levels
observed
in
eugonadal
men
.
Within
the
placebo
group
,
E
(
2
)
remained
at
baseline
levels
.
Of
the
endpoint
variables
measured
(
bone
metabolism
and
vascular
parameters
)
no
significant
changes
were
observed
compared
with
placebo
,
or
within
the
anastrozole-treated
group
.
These
results
may
indicate
that
the
negative
effects
of
estrogen
deprivation
in
men
only
become
manifest
when
the
concentration
falls
below
the
levels
induced
by
our
intervention
with
anastrozole
(
77
pmol
/
l
)
.
This
assumption
is
supported
by
the
observation
in
the
anastrozole
group
that
,
although
effects
of
the
reduction
of
serum
E
(
2
)
on
vascular
parameters
could
not
be
demonstrated
in
subjects
as
a
group
,
there
was
a
correlation
between
individual
serum
E
(
2
)
and
several
vascular
parameters
.
Diseases
Validation
Diseases presenting
"the cardiovascular system and biochemical variables of the metabolic syndrome"
symptom
aromatase deficiency
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom
